DOP009 Comparative safety profile of vedolizumab and tumour necrosis factor–antagonist therapy for inflammatory bowel disease: a multicentre consortium propensity score-matched analysis
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.